ARTHEx Biotech to Participate in the 2025 Jefferies Global Healthcare Conference

ARTHEx Biotech to Participate in the 2025 Jefferies Global Healthcare Conference News provided by ARTHEx Biotech May 29, 2025, 03:00 ET Share this article Share to X Share this article Share to X VALENCIA, Spain , May 29, 2025 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 2025 Jefferies Global Healthcare Conference, being held June 3-5, 2025 . Frédéric Legros, Executive Chairman and CEO, will participate in one-on-one meetings with investors during the conference. About ARTHEx Biotech ARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression. The Company's lead investigational compound, ATX-01, is being evaluated for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I-IIa ArthemiR™ trial. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1. The Company headquarters are in Valencia, Spain . For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn. Company Contact. Investor and Media Contact Frédéric Legros Executive Chairman and CEO [email protected] +33679495790 Amy Conrad Juniper Point [email protected] +1 858-366-3243 SOURCE ARTHEx Biotech 21 % more press release views with Request a Demo × Modal title